問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

陳友木
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳友木

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Thoracic Medicine

List

19Cases

2018-12-01 - 2027-12-31

Phase II/III

Active
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Tencentriq、Carboplatin-GRY、Cisplatin NeoCorp、Gitrabin、Alimta、Entrectinib、Cotellic、Zelboraf

Participate Sites
7Sites

Recruiting7Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2023-09-01 - 2029-12-31

Phase III

Active
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    VolrustomigKeytruda Injection

Participate Sites
13Sites

Recruiting13Sites

2019-03-06 - 2022-02-28

Phase II

Active
Phase 2 open trial to evaluate the safety and efficacy of Telisotuzumab Vedotin (ABBV-399) in subjects with previously treated c-Met+ non-small cell lung cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    Telisotuzumab Vedotin (ABBV-399)

Participate Sites
11Sites

Recruiting11Sites

2023-12-01 - 2031-05-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    注射劑 注射劑

Participate Sites
11Sites

Recruiting11Sites

2023-01-01 - 2029-05-19

Phase III

Active
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    MK-3475APembrolizumab (MK-3475)

Participate Sites
7Sites

Recruiting7Sites

2023-03-27 - 2029-07-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-07-01 - 2027-11-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2021-10-01 - 2027-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2024-04-01 - 2027-05-31

Phase III

Active
A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

  • Condition/Disease

    Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Recruiting6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB